Corvus Pharmaceuticals, Inc. reported a board change in a Form 8-K filed on July 22, 2026, disclosing that Ian T. Clark submitted notice on July 21, 2026 of his intention to resign from the company’s board of directors. Clark’s resignation became effective July 22, 2026. The filing was made under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and related compensatory arrangements. Corvus did not report any disagreement, dispute, or other stated reason connected to Clark’s departure, nor did the company disclose any related securities transactions, share sales, option exercises, compensation changes, or replacement appointment in the filing. The company thanked Clark for his “significant contributions” over more than nine years of board service. The filing was signed on behalf of Corvus Pharmaceuticals by Chief Financial Officer Leiv Lea on July 22, 2026. The disclosure matters because it marks the departure of a long-serving director from the governance structure of the clinical-stage biotechnology company, though the report does not indicate any immediate operational, strategic, or financial change tied to the resignation.